Growth hormone corrects vascular dysfunction in patients with chronic heart failure
Raffaele Napoli, MD*,
Vincenzo Guardasole, MD*,
Margherita Matarazzo, MD*,
Emiliano A. Palmieri, MD*,
Ugo Oliviero, MD*,
Serafino Fazio, MD* and
Luigi Saccà, MD*,*
* Department of Internal Medicine and Cardiovascular Sciences, University Federico II School of Medicine, Naples, Italy
View larger version (14K):
[in a new window]
|
Figure 1 Forearm blood flow response to acetylcholine (Ach) infusion in placebo- and growth hormone (GH)-treated patients at baseline and at the end of treatment. Data were analyzed by analysis of variance for repeated measures. p = NS for the basal response to Ach; p = 0.03 for the effect of GH treatment; p = 0.01 for the interaction between GH and ACh.
|
|
View larger version (17K):
[in a new window]
|
Figure 2 Forearm nitrite (upper panel) and cyclic guanosine monophosphate (cGMP) (lower panel) balance during intrabrachial acetlycholine infusion in placebo- and growth hormone (GH)-treated patients at baseline and at the end of treatment. *p < 0.05 versus the corresponding basal value; #0.1 > p > 0.05 versus the corresponding basal value. The signs (+) and (–) indicate uptake and release, respectively.
|
|
View larger version (17K):
[in a new window]
|
Figure 3 Forearm blood flow response to sodium nitroprusside (NP) infusion in the placebo- and growth hormone (GH)-treated patients at baseline and at the end of treatment. Data were analyzed by analysis of variance for repeated measures. p < 0.005 for the basal response to NP; p = 0.013 for the effect of GH treatment; p = NS for the interaction between GH and NP.
|
|
View larger version (15K):
[in a new window]
|
Figure 4 Relation between the slopes of the dose response curves to acetylcholine and the basal serum insulin-like growth factor I (IGF-I) concentrations.
|
|
|
